Symbols / APLM $14.72 +0.00% Apollomics, Inc.
APLM Chart
About
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 31.61M |
| Enterprise Value | 14.89M | Income | -31.19M | Sales | 6.93M |
| Book/sh | -3.99 | Cash/sh | 1.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -22.65 | PEG | — |
| P/S | 4.56 | P/B | -3.69 | P/C | — |
| EV/EBITDA | -0.56 | EV/Sales | 2.15 | Quick Ratio | 0.91 |
| Current Ratio | 0.97 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -26.64 | EPS next Y | -0.65 | EPS Growth | — |
| Revenue Growth | 3.81% | Earnings | — | ROA | -72.29% |
| ROE | -3.80% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -124.80% | Profit Margin | 0.00% | Shs Outstand | 2.15M |
| Shs Float | 594.35K | Short Float | 0.45% | Short Ratio | 1.07 |
| Short Interest | — | 52W High | 42.12 | 52W Low | 3.66 |
| Beta | 1.83 | Avg Volume | 10.56K | Volume | 713.00 |
| Target Price | — | Recom | None | Prev Close | $14.72 |
| Price | $14.72 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$14.00
Latest analyst target
3. DCF / Fair value
$-121.06
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-05-08 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-04-01 | main | EF Hutton | Buy → Buy | $7 |
| 2024-04-01 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $17 |
| 2023-10-03 | main | HC Wainwright & Co. | Buy → Buy | $17 |
| 2023-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-06-01 | init | HC Wainwright & Co. | — → Buy | $18 |
| 2023-04-25 | init | EF Hutton | — → Buy | $25 |
- Apollomics (APLM) chair reports 41.8% stake and $2M convertible bridge loan - Stock Titan Mon, 06 Apr 2026 17
- Biotech Apollomics gets $2M from its CEO to fund clinical programs - Stock Titan Wed, 01 Apr 2026 11
- Understanding the Setup: (APLM) and Scalable Risk - Stock Traders Daily Wed, 25 Mar 2026 05
- 12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga Mon, 30 Mar 2026 17
- Apollomics secures $2M convertible note from CEO Chen By Investing.com - Investing.com South Africa hu, 02 Apr 2026 10
- Nasdaq Halts Trading of Apollomics Inc. for Additional Information | NDAQ Stock News - Quiver Quantitative Wed, 17 Sep 2025 07
- Apollomics Inc. Announces $2.0 Million Bridge Financing - marketscreener.com Wed, 01 Apr 2026 11
- Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation - GlobeNewswire Wed, 15 Oct 2025 07
- APLM SEC Filings - APOLLOMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 11
- Nasdaq to resume trading of Apollomics shares after month-long halt - Investing.com ue, 14 Oct 2025 07
- CEO funds Apollomics (Nasdaq: APLM) with $2M zero-interest convertible note - Stock Titan Wed, 01 Apr 2026 20
- Director in Apollomics (APLM) reports 2,000 restricted stock units on Form 3 - Stock Titan Wed, 18 Mar 2026 07
- Apollomics (APLM) director Hong-Jung Chen discloses initial shares, RSUs, options and warrants - Stock Titan Wed, 18 Mar 2026 07
- Apollomics (APLM) director discloses 2,000 RSUs and vesting schedule - Stock Titan Wed, 18 Mar 2026 07
- Apollomics (APLM) director Huang Ya-Chi discloses 2,000 RSU grant in Form 3 - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
42.03
-22.69%
|
54.37
+22.49%
|
44.39
-11.70%
|
50.27
|
| Research And Development |
|
24.57
-28.15%
|
34.19
-3.56%
|
35.46
-0.31%
|
35.57
|
| Selling General And Administration |
|
17.77
-13.92%
|
20.64
+107.51%
|
9.95
-34.95%
|
15.29
|
| General And Administrative Expense |
|
17.77
-13.92%
|
20.64
+107.51%
|
9.95
-34.95%
|
15.29
|
| Other Gand A |
|
17.77
-13.92%
|
20.64
+107.51%
|
9.95
-34.95%
|
15.29
|
| Other Operating Expenses |
|
-0.30
+35.13%
|
-0.46
+54.33%
|
-1.02
-73.08%
|
-0.59
|
| Total Expenses |
|
42.03
-22.69%
|
54.37
+22.49%
|
44.39
-11.70%
|
50.27
|
| Operating Income |
|
-42.03
+22.69%
|
-54.37
-22.49%
|
-44.39
+11.70%
|
-50.27
|
| EBITDA |
|
-53.06
+69.11%
|
-171.77
+28.41%
|
-239.94
-155.17%
|
-94.03
|
| Normalized EBITDA |
|
-40.40
+76.75%
|
-173.78
+27.42%
|
-239.44
-162.91%
|
-91.07
|
| Reconciled Depreciation |
|
0.36
-46.04%
|
0.67
-13.68%
|
0.78
+13.80%
|
0.68
|
| EBIT |
|
-53.42
+69.02%
|
-172.44
+28.36%
|
-240.72
-154.15%
|
-94.71
|
| Total Unusual Items |
|
-12.66
-729.08%
|
2.01
+497.63%
|
-0.51
+82.92%
|
-2.96
|
| Total Unusual Items Excluding Goodwill |
|
-12.66
-729.08%
|
2.01
+497.63%
|
-0.51
+82.92%
|
-2.96
|
| Special Income Charges |
|
-13.00
|
0.00
|
0.00
+100.00%
|
-3.00
|
| Impairment Of Capital Assets |
|
13.00
|
0.00
|
0.00
-100.00%
|
3.00
|
| Net Income |
|
-53.86
+68.80%
|
-172.60
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Pretax Income |
|
-53.60
+68.94%
|
-172.59
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Net Non Operating Interest Income Expense |
|
0.30
-50.08%
|
0.60
+78.40%
|
0.34
-11.98%
|
0.38
|
| Interest Expense Non Operating |
|
0.18
+19.33%
|
0.15
+61.29%
|
0.09
+12.05%
|
0.08
|
| Net Interest Income |
|
0.30
-50.08%
|
0.60
+78.40%
|
0.34
-11.98%
|
0.38
|
| Interest Expense |
|
0.18
+19.33%
|
0.15
+61.29%
|
0.09
+12.05%
|
0.08
|
| Interest Income Non Operating |
|
0.48
-36.25%
|
0.75
+74.71%
|
0.43
-7.71%
|
0.47
|
| Interest Income |
|
0.48
-36.25%
|
0.75
+74.71%
|
0.43
-7.71%
|
0.47
|
| Other Income Expense |
|
-11.87
+90.01%
|
-118.82
+39.61%
|
-196.76
-338.14%
|
-44.91
|
| Other Non Operating Income Expenses |
|
0.79
+100.65%
|
-120.84
+38.43%
|
-196.25
-367.87%
|
-41.95
|
| Gain On Sale Of Security |
|
0.34
-82.95%
|
2.01
+497.63%
|
-0.51
-1431.58%
|
0.04
|
| Tax Provision |
|
0.26
+2490.00%
|
0.01
+900.00%
|
0.00
+0.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
-22.22%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-2.66
-729.08%
|
0.42
+497.63%
|
-0.11
+86.71%
|
-0.80
|
| Net Income Including Noncontrolling Interests |
|
-53.86
+68.80%
|
-172.60
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Net Income From Continuing Operation Net Minority Interest |
|
-53.86
+68.80%
|
-172.60
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Net Income From Continuing And Discontinued Operation |
|
-53.86
+68.80%
|
-172.60
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Net Income Continuous Operations |
|
-53.86
+68.80%
|
-172.60
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Normalized Income |
|
-43.86
+74.82%
|
-174.19
+27.54%
|
-240.41
-159.53%
|
-92.63
|
| Net Income Common Stockholders |
|
-53.86
+68.80%
|
-172.60
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Diluted EPS |
|
—
|
-231.99
-7650.04%
|
-2.99
-154.03%
|
-1.18
|
| Basic EPS |
|
—
|
-231.99
-7650.04%
|
-2.99
-154.03%
|
-1.18
|
| Basic Average Shares |
|
—
|
0.74
-99.08%
|
80.45
+0.00%
|
80.45
|
| Diluted Average Shares |
|
—
|
0.74
-99.08%
|
80.45
+0.00%
|
80.45
|
| Diluted NI Availto Com Stockholders |
|
-53.86
+68.80%
|
-172.60
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
13.10
-76.35%
|
55.39
-27.58%
|
76.47
-38.05%
|
123.44
|
| Current Assets |
|
10.27
-74.28%
|
39.92
-28.44%
|
55.79
-43.86%
|
99.37
|
| Cash Cash Equivalents And Short Term Investments |
|
9.77
-74.18%
|
37.82
-30.76%
|
54.61
-42.20%
|
94.48
|
| Cash And Cash Equivalents |
|
9.77
-69.53%
|
32.06
-1.89%
|
32.67
-30.09%
|
46.74
|
| Other Short Term Investments |
|
0.00
-100.00%
|
5.76
-73.74%
|
21.94
-54.05%
|
47.74
|
| Receivables |
|
0.13
-72.75%
|
0.47
-14.81%
|
0.55
+8.10%
|
0.51
|
| Taxes Receivable |
|
0.13
-72.75%
|
0.47
-14.81%
|
0.55
+8.10%
|
0.51
|
| Prepaid Assets |
|
0.37
-77.22%
|
1.64
+161.05%
|
0.63
-70.37%
|
2.12
|
| Current Deferred Assets |
|
—
|
—
|
0.00
-100.00%
|
2.25
|
| Total Non Current Assets |
|
2.83
-81.69%
|
15.46
-25.25%
|
20.68
-14.06%
|
24.07
|
| Net PPE |
|
1.02
+73.89%
|
0.59
-60.30%
|
1.48
+12.16%
|
1.32
|
| Gross PPE |
|
1.51
-52.31%
|
3.16
-17.86%
|
3.85
+28.83%
|
2.99
|
| Accumulated Depreciation |
|
-0.49
+80.99%
|
-2.58
-8.50%
|
-2.38
-41.94%
|
-1.67
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.98
-61.85%
|
2.57
-10.16%
|
2.87
+21.04%
|
2.37
|
| Machinery Furniture Equipment |
|
0.40
-11.43%
|
0.46
-46.60%
|
0.85
+74.59%
|
0.49
|
| Leases |
|
0.12
-8.15%
|
0.14
+0.00%
|
0.14
+0.00%
|
0.14
|
| Goodwill And Other Intangible Assets |
|
1.74
-88.23%
|
14.76
-0.14%
|
14.78
-0.14%
|
14.80
|
| Other Intangible Assets |
|
1.74
-88.23%
|
14.76
-0.14%
|
14.78
-0.14%
|
14.80
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
4.31
-45.08%
|
7.84
|
| Other Investments |
|
—
|
0.00
-100.00%
|
4.31
-45.08%
|
7.84
|
| Non Current Prepaid Assets |
|
0.07
-36.97%
|
0.12
-4.03%
|
0.12
+9.73%
|
0.11
|
| Total Liabilities Net Minority Interest |
|
8.23
-41.82%
|
14.15
-97.30%
|
524.60
+55.99%
|
336.30
|
| Current Liabilities |
|
7.40
-45.42%
|
13.56
+9.70%
|
12.36
-8.84%
|
13.56
|
| Payables And Accrued Expenses |
|
7.17
-21.79%
|
9.16
-21.52%
|
11.68
+2.40%
|
11.40
|
| Payables |
|
1.25
-79.10%
|
5.97
-20.79%
|
7.54
+25.49%
|
6.01
|
| Other Payable |
|
1.25
-79.10%
|
5.97
-20.79%
|
7.54
+25.49%
|
6.01
|
| Current Accrued Expenses |
|
5.92
+85.46%
|
3.19
-22.87%
|
4.14
-23.30%
|
5.39
|
| Total Tax Payable |
|
—
|
—
|
—
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.23
-94.70%
|
4.39
+615.64%
|
0.61
+20.87%
|
0.51
|
| Current Debt |
|
—
|
4.24
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.23
+47.47%
|
0.16
-74.27%
|
0.61
+20.87%
|
0.51
|
| Current Deferred Liabilities |
|
—
|
—
|
1.00
+0.00%
|
1.00
|
| Other Current Liabilities |
|
—
|
—
|
0.07
-95.87%
|
1.65
|
| Total Non Current Liabilities Net Minority Interest |
|
0.83
+39.87%
|
0.60
-99.88%
|
512.24
+58.71%
|
322.74
|
| Long Term Debt And Capital Lease Obligation |
|
0.73
+174.53%
|
0.27
-29.18%
|
0.38
-28.60%
|
0.53
|
| Long Term Capital Lease Obligation |
|
0.73
+174.53%
|
0.27
-29.18%
|
0.38
-28.60%
|
0.53
|
| Other Non Current Liabilities |
|
—
|
—
|
511.86
+58.86%
|
322.21
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
511.86
+58.86%
|
322.21
|
| Stockholders Equity |
|
4.86
-88.20%
|
41.23
+109.20%
|
-448.12
-110.52%
|
-212.86
|
| Common Stock Equity |
|
4.86
-88.20%
|
41.23
+109.20%
|
-448.12
-110.52%
|
-212.86
|
| Capital Stock |
|
0.01
+22.22%
|
0.01
-78.05%
|
0.04
+2.50%
|
0.04
|
| Common Stock |
|
0.01
+22.22%
|
0.01
-78.05%
|
0.04
+2.50%
|
0.04
|
| Share Issued |
|
1.10
+23.22%
|
0.89
-98.89%
|
80.45
+0.00%
|
80.45
|
| Ordinary Shares Number |
|
1.10
+23.22%
|
0.89
-98.89%
|
80.45
+0.00%
|
80.45
|
| Additional Paid In Capital |
|
666.53
+0.76%
|
661.47
+5287.03%
|
12.28
+3.29%
|
11.89
|
| Retained Earnings |
|
-700.82
-8.32%
|
-646.97
-36.32%
|
-474.60
-101.58%
|
-235.44
|
| Gains Losses Not Affecting Retained Earnings |
|
3.44
+0.00%
|
3.44
+1.09%
|
3.40
+39.26%
|
2.44
|
| Treasury Stock |
|
0.00
|
0.00
-100.00%
|
0.07
-95.87%
|
1.65
|
| Other Equity Adjustments |
|
3.44
+0.00%
|
3.44
+1.09%
|
3.40
+39.26%
|
2.44
|
| Total Equity Gross Minority Interest |
|
4.86
-88.20%
|
41.23
+109.20%
|
-448.12
-110.52%
|
-212.86
|
| Total Capitalization |
|
4.86
-88.20%
|
41.23
+109.20%
|
-448.12
-110.52%
|
-212.86
|
| Working Capital |
|
2.87
-89.12%
|
26.37
-39.29%
|
43.43
-49.39%
|
85.81
|
| Invested Capital |
|
4.86
-89.30%
|
45.47
+110.15%
|
-448.12
-110.52%
|
-212.86
|
| Total Debt |
|
0.97
-79.27%
|
4.66
+370.33%
|
0.99
-4.34%
|
1.04
|
| Capital Lease Obligations |
|
0.97
+127.29%
|
0.42
-57.11%
|
0.99
-4.34%
|
1.04
|
| Net Tangible Assets |
|
3.13
-88.19%
|
26.48
+105.72%
|
-462.90
-103.33%
|
-227.66
|
| Tangible Book Value |
|
3.13
-88.19%
|
26.48
+105.72%
|
-462.90
-103.33%
|
-227.66
|
| Derivative Product Liabilities |
|
0.10
-69.09%
|
0.33
|
0.00
|
—
|
| Line Of Credit |
|
0.00
-100.00%
|
4.24
|
0.00
|
—
|
| Other Equity Interest |
|
35.71
+53.40%
|
23.28
+114.97%
|
10.83
+9.93%
|
9.85
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-28.74
+33.48%
|
-43.21
-0.90%
|
-42.82
+1.13%
|
-43.31
|
| Cash Flow From Continuing Operating Activities |
|
-28.74
+33.48%
|
-43.21
-0.90%
|
-42.82
+1.13%
|
-43.31
|
| Net Income From Continuing Operations |
|
-53.60
+68.94%
|
-172.59
+28.33%
|
-240.81
-154.03%
|
-94.80
|
| Depreciation Amortization Depletion |
|
0.36
-46.04%
|
0.67
-13.68%
|
0.78
+13.80%
|
0.68
|
| Depreciation |
|
0.34
-47.46%
|
0.65
-14.04%
|
0.76
+14.22%
|
0.66
|
| Amortization Cash Flow |
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
|
| Depreciation And Amortization |
|
0.36
-46.04%
|
0.67
-13.68%
|
0.78
+13.80%
|
0.68
|
| Amortization Of Intangibles |
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
|
| Other Non Cash Items |
|
-0.01
-100.01%
|
44.83
+13361.83%
|
-0.34
+11.98%
|
-0.38
|
| Stock Based Compensation |
|
10.93
-13.87%
|
12.69
+254.13%
|
3.58
-55.90%
|
8.12
|
| Asset Impairment Charge |
|
13.00
|
0.00
|
0.00
-100.00%
|
3.00
|
| Operating Gains Losses |
|
0.02
+133.96%
|
-0.05
+97.21%
|
-1.90
|
—
|
| Gain Loss On Investment Securities |
|
—
|
0.04
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
-0.22
-100.30%
|
74.83
-60.47%
|
189.32
+405.91%
|
37.42
|
| Net Foreign Currency Exchange Gain Loss |
|
0.00
+100.00%
|
-0.28
+85.32%
|
-1.90
|
0.00
|
| Gain Loss On Sale Of PPE |
|
0.02
-90.43%
|
0.19
|
0.00
|
0.00
|
| Change In Working Capital |
|
1.04
+129.07%
|
-3.57
-154.98%
|
6.49
+145.48%
|
2.64
|
| Change In Prepaid Assets |
|
1.61
+272.53%
|
-0.93
-125.53%
|
3.65
+905.96%
|
-0.45
|
| Change In Payables And Accrued Expense |
|
-0.57
+78.33%
|
-2.63
-192.88%
|
2.84
-8.37%
|
3.10
|
| Change In Payable |
|
-0.57
+78.33%
|
-2.63
-192.88%
|
2.84
-8.37%
|
3.10
|
| Investing Cash Flow |
|
5.98
-72.00%
|
21.36
-26.46%
|
29.05
+174.59%
|
-38.95
|
| Cash Flow From Continuing Investing Activities |
|
5.98
-72.00%
|
21.36
-26.46%
|
29.05
+174.59%
|
-38.95
|
| Net PPE Purchase And Sale |
|
-0.02
-138.46%
|
0.05
+114.17%
|
-0.37
-634.00%
|
-0.05
|
| Purchase Of PPE |
|
-0.02
-300.00%
|
-0.01
+98.37%
|
-0.37
-634.00%
|
-0.05
|
| Sale Of PPE |
|
0.00
-93.10%
|
0.06
|
0.00
|
0.00
|
| Capital Expenditure |
|
-0.02
-300.00%
|
-0.01
+98.37%
|
-0.37
+95.14%
|
-7.55
|
| Net Investment Purchase And Sale |
|
5.76
-71.88%
|
20.49
-29.36%
|
29.00
+191.07%
|
-31.84
|
| Purchase Of Investment |
|
—
|
—
|
0.00
+100.00%
|
-103.79
|
| Sale Of Investment |
|
5.76
-71.88%
|
20.49
-29.36%
|
29.00
-59.69%
|
71.95
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-7.50
|
| Purchase Of Intangibles |
|
—
|
0.00
|
0.00
+100.00%
|
-7.50
|
| Net Other Investing Changes |
|
0.04
+780.00%
|
0.01
+145.45%
|
-0.01
+56.00%
|
-0.03
|
| Financing Cash Flow |
|
0.47
-97.80%
|
21.23
+7319.39%
|
-0.29
+82.11%
|
-1.64
|
| Cash Flow From Continuing Financing Activities |
|
0.47
-97.80%
|
21.23
+7319.39%
|
-0.29
+82.11%
|
-1.64
|
| Net Issuance Payments Of Debt |
|
0.66
-97.25%
|
24.04
+4154.13%
|
-0.59
-12.31%
|
-0.53
|
| Issuance Of Debt |
|
5.75
-76.51%
|
24.48
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-5.09
-1046.40%
|
-0.44
+25.13%
|
-0.59
-12.31%
|
-0.53
|
| Long Term Debt Issuance |
|
5.05
-75.07%
|
20.25
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-0.17
+61.71%
|
-0.44
+25.13%
|
-0.59
-12.31%
|
-0.53
|
| Net Long Term Debt Issuance |
|
4.88
-75.36%
|
19.80
+3439.80%
|
-0.59
-12.31%
|
-0.53
|
| Short Term Debt Issuance |
|
0.70
-83.43%
|
4.24
|
0.00
|
0.00
|
| Short Term Debt Payments |
|
-4.92
|
0.00
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
-4.22
-199.58%
|
4.24
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
—
|
—
|
0.39
+178.01%
|
0.14
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.09
-78.32%
|
0.39
+178.01%
|
0.14
|
| Net Other Financing Charges |
|
—
|
-2.78
|
—
|
-1.17
|
| Changes In Cash |
|
-22.29
-3501.29%
|
-0.62
+95.60%
|
-14.06
+83.24%
|
-83.91
|
| Effect Of Exchange Rate Changes |
|
0.00
|
0.00
|
0.00
|
—
|
| Beginning Cash Position |
|
32.06
-1.89%
|
32.67
-30.09%
|
46.74
-64.22%
|
130.65
|
| End Cash Position |
|
9.77
-69.53%
|
32.06
-1.89%
|
32.67
-30.09%
|
46.74
|
| Free Cash Flow |
|
-28.77
+33.43%
|
-43.22
-0.06%
|
-43.19
+15.08%
|
-50.86
|
| Common Stock Issuance |
|
—
|
—
|
0.39
+178.01%
|
0.14
|
| Interest Paid CFF |
|
-0.19
-58.20%
|
-0.12
-31.18%
|
-0.09
-12.05%
|
-0.08
|
| Interest Received CFI |
|
0.20
-75.88%
|
0.82
+90.49%
|
0.43
-7.71%
|
0.47
|
| Issuance Of Capital Stock |
|
—
|
—
|
0.39
+178.01%
|
0.14
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Taxes Refund Paid |
|
-0.26
-2490.00%
|
-0.01
-117.86%
|
0.06
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|